Position Summary: The in vivo functional genomic laboratory of Dr. Giannicola Genovese at the University of Texas at MD Anderson Cancer Center in Houston, TX is looking for an exceptional postdoctoral fellow with a strong interest in understanding the mechanisms and dynamics of clonal evolution in the progression of aggressive solid tumors. The successful candidate will have significant experience in cancer genetics/genomics and immunology. Experience with molecular biology, histology and tissue preparation, cell biology are very helpful but not required.
What we offer:
The aim of our research is to dissect the mechanisms driving clonal diversification in malignant progression with a focus on functional determinants of metastatic dissemination and immune evasion. We address these fundamental questions in high-throughput in vivo models of cancer leveraging somatic mosaic genome editing methods and complex lineage/clonal tracing tools.
- Training and expertise in genetics and functional genomics (in vivo somatic genetic/chromosomal engineering).
- A stimulating environment with freedom to develop new research directions.
- The opportunity to work with the world leaders in cancer genomics.
- Supportive mentorship for career development and opportunities tailored towards individual career goals and strengths.
- A fun, hard-working and supportive lab that practices team-based science.
What we’re looking for:
- Ideally someone who is less than one year out from completing their PhD, however each candidate with a strong interest in science and cancer medicine is encouraged to apply.
- An enthusiastic and ambitious individual with a strong curiosity and a desire to learn.
- An independent thinker that works well in a team.
- Strong verbal and written communication skills.
- Willing to take advantage of career development opportunities.
- Interest in working with junior lab members and summer undergraduates.
- Start date: Immediately.
Application materials (important to follow directions)
· Cover letter outlining relevant expertise and scientific interests pertinent to our lab and your future projects. This letter will be a way to assess your thought process and writing skills.
· Updated CV/Biosketch
· Contact information for three references
Please email these three items to: ggenovese@MDAnderson.org
Carugo A*, Genovese G*, Seth S*, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D’Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinho RA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016; 16(1):133-47. PubMed PMID: 27320920. Co-first author
Genovese G, Carugo A, Tepper J, Robinson FS, Li L, 4, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Dal Molin M, Ying H, Kwong L, Colla S, Takahashi K, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan T, Toniatti C, Fleming J, Viale A, Gog-gins M, Wood L, Agaimy A, Sgambato A, Maitra A, Roberts CW, Wang H, Draetta G, Chin L. Synthetic vulnerabilities in mesenchymal sub-populations of pancreatic cancer cells undergoing anabolic reprogramming. Nature. 2017; 542(7641):362-6. PubMed PMID: 28178232. Corresponding author.
Carugo A*, Minelli R*, Sapio L*, Soeung M, Carbone F, Msaouel P, Viale A, Roberts CW, Tannir N, Draetta G, Genovese G; p53 is a master regulator of proteostasis in SMARCB1 deficient malignant rhabdoid tumors. Cancer Cell (2019) https://doi.org/10.1016/j.ccell.2019.01.006. Corresponding author
Genovese G*, Ergun A*, Shukla SA*, Campos B, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Wiedemeyer WR, Brennan C, Zheng H, Collins JJ, Chin L. microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-? Signaling in Glioblastoma. Cancer Discov. 2012; 2(8):736-49. PubMed PMCID: PMC3911772.
Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature. 2012 Aug16;488 (7411):337-42. doi: 10.1038/nature11331.
For a full list of publications please see